Sources
CJC-1295 Ipamorelin references: the cited literature in full
Every quantitative claim on this site maps to one of these peer-reviewed sources, with DOI and PubMed links.
How to read this list
Every numbered citation [N] used across the CJC-1295 Ipamorelin pages corresponds to an entry below, with authors, journal, year, and a DOI or PubMed link where available. The list spans the foundational synergy work (Bowers 1990; Cunha 2002), the CJC-1295 human pharmacokinetics (Teichman 2006; Ionescu 2006), the DAC chemistry (Jetté 2005), ipamorelin's defining selectivity study (Raun 1998), the GH-secretagogue safety review (Sigalos 2018), and class-level and read-across evidence (the TZP-101 postoperative-ileus studies; the tesamorelin meta-analysis). Where a study used a related peptide rather than the fixed blend, that is stated in the body text that cites it — the references here are the primary sources, read in context on the page that uses them.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. ↗
- Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. ↗
- Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. ↗
- Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. ↗
- Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. ↗
- Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. ↗
- Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871-1887. ↗
- Ionescu M, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. ↗
- Ho KY, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988;81(4):968-75. ↗
- Fraser GL, et al. Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus. Eur J Pharmacol. 2009;604(1-3):132-7. ↗
- Venkova K, et al. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus. Dig Dis Sci. 2007;52(9):2241-8. ↗
- Halmos G, et al. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025. ↗
- Gouda M, et al. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Anim Reprod Sci. 2024;266:107550. ↗